Role of mpMRI in Benign Prostatic Hyperplasia Assessment and Treatment.
BPH
Benign prostatic hyperplasia
LUTS
Prostate MRI
Urinary incontinence
mpMRI
Journal
Current urology reports
ISSN: 1534-6285
Titre abrégé: Curr Urol Rep
Pays: United States
ID NLM: 100900943
Informations de publication
Date de publication:
26 Oct 2020
26 Oct 2020
Historique:
accepted:
15
10
2020
entrez:
26
10
2020
pubmed:
27
10
2020
medline:
4
3
2021
Statut:
epublish
Résumé
To summarize the role of prostate MRI in the assessment and treatment of benign prostatic hyperplasia (BPH) and associated lower urinary tract symptoms (LUTS). BPH/LUTS is a very common source of morbidity in aging men. mpMRI has become an increasingly popular modality for prostate imaging due to its ability to provide exceptional anatomic detail. This has allowed for MRI classification of BPH and detailed assessment of response to various BPH treatment modalities, including simple prostatectomy and transurethral resection of the prostate as well as newer methods like UroLift and prostatic artery embolization. MRI will continue to be a useful tool in the diagnosis and management of BPH/LUTS and provides useful information about the efficacy of a variety of available treatment options. Further studies are needed to fully characterize the effects of newer BPH interventions on mpMRI.
Identifiants
pubmed: 33104969
doi: 10.1007/s11934-020-01005-x
pii: 10.1007/s11934-020-01005-x
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM